

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

13 APR. 1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07C 215/48, 215/52, 217/60, 225/20, A61K 31/135</b>	A1	(11) International Publication Number: <b>WO 99/15494</b> (43) International Publication Date: <b>1 April 1999 (01.04.99)</b>
(21) International Application Number: <b>PCT/IT98/00252</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>22 September 1998 (22.09.98)</b>		
(30) Priority Data: <b>RM97A000568 22 September 1997 (22.09.97) IT</b>		
(71) Applicant (for all designated States except US): <b>SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Roma (IT).</b>		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): <b>FANTO, Nicola [IT/IT]; Viale Pico della Mirandola, 50, I-00142 Roma (IT). MORETTI, Gian, Piero [IT/IT]; Via Marco Valerio Corvo, 58, I-00174 Roma (IT). FORESTA, Piero [IT/IT]; Via L. Sturzo, 46, I-00040 Pomezia (IT).</b>		
(74) Common Representative: <b>SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.; Viale Shakespeare, 47, I-00144 Roma (IT).</b>		

(54) Title: **2-AMINOTETRALINES, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE PATHOLOGIES**

(57) Abstract

2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory pathologies (particularly septic shock) and/or autoimmune pathologies in which the aetiopathogenic role of inflammatory cytokines has been ascertained.

1  
JC135 U.S. PTO 09/533281  
03/22/00